The CDC Public Health Cancer Genomics Program: Translating Research into Public Health Practice

The Department of Health and Human Services Centers for Disease Control and Prevention funds translation of evidence-based cancer genomics recommendations into public health practice under Assistance Listing 93.380, with the most recent grant awards issued on September 30, 2019.

Program activity has stalled. The CDC disbursed three Cooperative Agreements totaling $5.3 million in September 2019 and has not awarded grants under this program since that date—more than seven years ago. No recent grant opportunities are posted. The source documents a single solicitation (CDC-RFA-DP19-1905) that closed on April 15, 2019, making this program inactive from a business development perspective.

When active, the program funded state-level cancer genomics initiatives addressing hereditary breast and ovarian cancer (HBOC) and Lynch Syndrome (LS). Funded activities included family cancer history screening programs, provider education on genetic testing referral, surveillance systems to measure hereditary cancer burden, and health system policy interventions to expand access to cancer genetic counseling and testing. All awards in the portfolio were Cooperative Agreements exclusively.

The three recipients awarded in 2019 received funding magnitudes ranging from roughly $1.4 million to $2.1 million. The Michigan Department of Health and Human Services received $2,077,793 to advance cancer genomics best practices statewide, targeting rural areas and working toward systems of care aligned with national clinical guidelines for HBOC and Lynch Syndrome–related cancers. Two additional recipients received awards of $1,810,000 and $1,383,153 for related cancer genomics programming and evaluation.

The CDC was the sole funding agency across the three awards. No successor solicitations have been posted since April 2019, and the most recent award completion dates range from 2022 to 2023. Applicants should verify current program status with CDC's Division of Cancer Prevention and Control before investing significant business development effort; this Assistance Listing may be inactive or consolidated under a different program vehicle.